Novartis Coartem NDA May Lead to First Priority Review Voucher
This article was originally published in RPM Report
Executive Summary
Malaria drug receives "priority" status from FDA, which should mean Novartis receives a voucher for priority designation on another product under new incentive program for tropical disease research. December application deadline also sets a deadline for FDA to defi ne key elements of how PRVs will work.